← Browse by Condition
Medical Condition

neonatal encephalopathy

Total Trials
3
Recruiting Now
3
Trial Phases
EARLY_Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for neonatal encephalopathy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neonatal encephalopathy Clinical Trials

How many clinical trials are currently recruiting for neonatal encephalopathy?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for neonatal encephalopathy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neonatal encephalopathy?
neonatal encephalopathy research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neonatal encephalopathy clinical trial?
Eligibility criteria for neonatal encephalopathy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
Boston Children's Hospital 1 trial
Semmelweis University 1 trial
Pharmazz, Inc. 1 trial

Recruiting Clinical Trials

NCT07165938
Recruiting

Genetics of Neonatal Encephalopathy and Related Disorders

Enrollment
300 pts
Location
United States
Sponsor
Boston Children's Hospital
View Trial →
NCT06746532 EARLY_Phase 1
Recruiting

Intranasal Breast Milk Therapy in HIE

Enrollment
80 pts
Location
Hungary
Sponsor
Semmelweis University
View Trial →
NCT05514340 Phase 2
Recruiting

Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy

Enrollment
40 pts
Location
India
Sponsor
Pharmazz, Inc.
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology